Latest Articles
Aga Khan Hospital: Woman removed womb without consent to be paid Sh157 million - Bizna Kenya
Aga Khan Hospital: Woman removed womb without consent to be paid Sh157 million Bizna Kenya
Published: June 5, 2025, 9:31 a.m.
‘DWTS’ pro recounts scary medical emergency she suffered on live TV when she was just 18: ‘I had a...’ - MEAWW
‘DWTS’ pro recounts scary medical emergency she suffered on live TV when she was just 18: ‘I had a...’ MEAWW
Published: June 4, 2025, 9:53 p.m.
Correlation Between Hormonal Modulation and Pregnancy Outcomes: The Impact of Estrogen Priming and Endometrial Receptivity in Intrauterine Insemination - Cureus
Correlation Between Hormonal Modulation and Pregnancy Outcomes: The Impact of Estrogen Priming and Endometrial Receptivity in Intrauterine Insemination Cureus
Published: June 4, 2025, 3:34 p.m.
newsGP - New hope for pelvic pain management - Royal Australian College of General Practitioners (RACGP)
newsGP - New hope for pelvic pain management Royal Australian College of General Practitioners (RACGP)
Published: June 4, 2025, 6:44 a.m.
New endometriosis and chronic pelvic pain management plan to be trialled in Australia - Monash University
New endometriosis and chronic pelvic pain management plan to be trialled in Australia Monash University
Published: June 4, 2025, 2:15 a.m.
'DWTS' Pro Reveals Scary Health Emergency Suffered on Live TV - parade.com
'DWTS' Pro Reveals Scary Health Emergency Suffered on Live TV parade.com
Published: June 3, 2025, 5:25 p.m.
Robert Irwin Calls Sister Bindi a "Tough Person" After Medical Emergency - MSN
Robert Irwin Calls Sister Bindi a "Tough Person" After Medical Emergency MSN
Published: June 3, 2025, 7:31 a.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - BioSpace
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial BioSpace
Published: June 2, 2025, 11:48 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - GlobeNewswire
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial GlobeNewswire
Published: June 2, 2025, 6:32 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo Finance
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo Finance
Published: June 2, 2025, 6:30 p.m.
Link copied to clipboard!